RxDoctor Payments Data

Chad Smoker, MD

Family Medicine · New Paris, INNPI 1932193380

Payments from drug & device makers

$232in general payments, 2019–2025

Across 15 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$41
  • Baxter Healthcare$41
  • Alnylam Pharmaceuticals Inc.$35
  • Sanofi-aventis U.S. LLC$27
  • Novo Nordisk$18
  • Pfizer$16
  • plus $55 from 4 others

What the payments were for

  • Food & beverage$232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$232 in reported general payments places this provider in the 35th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$117,279
Medicare patients
310
Services billed
2,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$196,610
OzempicSemaglutide145$159,672
JardianceEmpagliflozin129$116,846
TrulicityDulaglutide84$92,236
XareltoRivaroxaban67$69,054
Soliqua 100-33Insulin Glargine/Lixisenatide56$46,630
RybelsusSemaglutide27$38,261
MyrbetriqMirabegron36$25,410
JanuviaSitagliptin Phosphate17$20,425
UbrelvyUbrogepant16$17,877
EntrestoSacubitril/Valsartan14$17,152
FarxigaDapagliflozin Propanediol16$17,043
ElmironPentosan Polysulfate Sodium12$16,005
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$15,509
Potassium Chloride155$14,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$16$201,923289 claims
Novo NordiskOzempic, Rybelsus$18$197,932172 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$27$46,63056 claims
AstraZenecaFarxiga, Symbicort$41$30,34857 claims
AbbVieUbrelvy, Creon, Viibryd$15$27,76843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in New Paris

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →